Rapid Discovery of Pyrido[3,4- d ]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach by Innocenti, P et al.
Rapid Discovery of Pyrido[3,4‑d]pyrimidine Inhibitors of Monopolar
Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization
Approach
Paolo Innocenti,† Hannah L. Woodward,† Savade Solanki,† Seb́astien Naud,† Isaac M. Westwood,†,‡
Nora Cronin,‡ Angela Hayes,† Jennie Roberts,† Alan T. Henley,† Ross Baker,† Amir Faisal,†,∥
Grace Wing-Yan Mak,† Gary Box,† Melanie Valenti,† Alexis De Haven Brandon,† Lisa O’Fee,†
Harry Saville,† Jessica Schmitt,† Berry Matijssen,† Rosemary Burke,† Rob L. M. van Montfort,†,‡
Florence I. Raynaud,† Suzanne A. Eccles,† Spiros Linardopoulos,†,§ Julian Blagg,† and Swen Hoelder*,†
†Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold
Road, Sutton, London, SM2 5NG, United Kingdom
‡Division of Structural Biology and §Breast Cancer Now, Division of Breast Cancer Research, The Institute of Cancer Research, 237
Fulham Road, London, SW3 6JB, United Kingdom
*S Supporting Information
ABSTRACT: Monopolar spindle 1 (MPS1) plays a central role in the transition of cells from metaphase to anaphase and is one
of the main components of the spindle assembly checkpoint. Chromosomally unstable cancer cells rely heavily on MPS1 to cope
with the stress arising from abnormal numbers of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition
than normal cells. We report the discovery and optimization of a series of new pyrido[3,4-d]pyrimidine based inhibitors via a
structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit.
Compounds in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation
in an in vivo human tumor xenograft model.
■ INTRODUCTION
Interfering with mitotic processes has been a successful
therapeutic approach to ﬁght cancer.1 One example of a mitotic
target is monopolar spindle 1 (MPS1, also known as TTK), a
dual-speciﬁcity kinase that occupies a central role in the
transition from metaphase to anaphase and is one of the main
components of the spindle assembly checkpoint (SAC).2 This
kinase prevents cells from progressing through mitosis until the
kinetochores are properly attached to the microtubules and are
under the appropriate tension. While this mechanism is
important to ensure error-free segregation of chromosomes in
normal tissues, aneuploid and chromosomally unstable cancer
cells often overexpress, and are particularly dependent on, MPS1
to cope with the stress arising from abnormal numbers of
chromosomes and centrosomes.3 Due to these ﬁndings, it is not
surprising that MPS1 is upregulated in a number of tumor types4
and that higher levels correlate with higher histological grade,
aggressiveness, and poorer patient survival in breast cancer,
glioblastoma, and pancreatic ductal adenocarcinoma.4a,5 Fur-
thermore, phosphatase and tensin homologue (PTEN)-deﬁcient
breast cancer cell lines have been reported to bemore sensitive to
MPS1 depletion or kinase inhibition.3b,6
Using advanced inhibitors, including our own 1 (CCT251455,
vide infra),7 eﬀective dosing schedules have been investigated in
vivo. Importantly, it has recently been shown that MPS1
inhibitors have a relatively narrow therapeutic window5a,8 and
that they are particularly eﬀective when used in combination
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with, for example, tubulin-targeting agents such as paclitaxel or
CDK4/6 inhibitors.9
Several MPS1 inhibitors have been disclosed,10 these include
AstraZeneca’s AZ3146 (2),10b the Myrexis compound MPI-
0479605 (3),8c and the Nerviano compound NMS-P715 (4).11
Also described in the literature are MPS-IN-3 (5),5a CFI-401870
(6),12 and the Shionogi compounds (7, 8) (Figure 1).8a,13
We recently disclosed a series of 1H-pyrrolo[3,2-c]pyridines
exempliﬁed by the potent and selective chemical probe 1.7
However, while this compound showed excellent potency in
biochemical and cellular assays, other properties hampered
further development. In particular, 1 has a relatively high
molecular weight (504) and AlogP (5.7) and also featured a tert-
butoxycarbonyl (Boc) moiety that appeared critical for potent
inhibition but unsurprisingly proved to be unstable under
strongly acidic conditions.14 In addition, 1 was a potent
cytochrome P450 (CYP) inhibitor (IC50 < 1 μM observed for
CYP 1A2, 3A4, 2C9, 2C19, 2D6) which represented a signiﬁcant
issue not least because MPS1 inhibitors are reported to be
particularly eﬀective in combination with other chemotherapeu-
tic agents, e.g., paclitaxel. To mitigate the risk that these
undesirable features were inherent to the 1H-pyrrolo[3,2-
c]pyridine series, we set out to discover a second structurally
unrelated chemotype featuring a clean CYP proﬁle, no acid labile
groups, and signiﬁcantly lower molecular weight and lip-
ophilicity. We thus set out to discover an additional lead series
that (a) showed potent inhibition of MPS1 in cellular assays
(IC50 < 100 nM), (b) showed good ligand eﬃciency (L.E. ∼
0.35),15 (c) displayed excellent selectivity, in particular against
other cell cycle kinases such as cyclin-dependent kinase 2
(CDK2), Aurora A and B, and more generally against the wider
kinome (Ki ratio >100), (d) robustly modulated MPS1 kinase
activity in a human tumor xenograft PK/PD model, and (e)
showed signiﬁcant scope for further modiﬁcation.
Herein we describe the rapid discovery of such a series by
structure-based hybridization of the 1H-pyrrolo[3,2-c]pyridine
series and a modestly potent hit from a focused kinase library
screen. This completely new MPS1 series featured an
unexploited kinase chemotype (the pyrido[3,4-d]pyrimidines)
and advanced examples displayed subnanomolar Kis and
excellent overall selectivity. The favorable in vitro properties
translated into biomarker modulation in an in vivo human tumor
xenograft model.
■ CHEMISTRY
The synthesis of isoquinolines 14, 15a and 15b was carried out
from the commercially available 5-bromo-3-chloroisoquinoline 9
through sequential Suzuki couplings and Buchwald reactions
using suitable boronic acids or esters and the required anilines
(Scheme 1).
Compounds 24a−d and 28a−e in the pyrido[3,4-d]-
pyrimidine series were prepared according to a previously
described strategy which makes use of the novel 8-chloro-2-
(methylthio)pyrido[3,4-d]pyrimidine building block 16.16 Thus,
reaction with 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboro-
lan-2-yl)-1H-pyrazole or cyclopropylboronic acid under Suzuki
conditions yielded intermediates 17 and 18. These thiomethyl
derivatives were in turn oxidized to the corresponding sulfones
Figure 1. Published MPS1 inhibitors.
Scheme 1. Synthesis of Isoquinoline Derivativesa
aReagents and conditions: (a) Furan-2-ylboronic acid or 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, Na2CO3,
Pd(dppf)Cl2·CH2Cl2, DME/water, μW, 105 °C; (b) 4-methoxyaniline 12 or 2,4-dimethoxyaniline 13,
tBuXPhos, Pd2dba3, Cs2CO3,
tBuOH/
water, μW, 80−100 °C. Reaction yields are in parentheses.
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using m-CPBA and subsequently coupled with the required
anilines or formamides to aﬀord compounds 24a−d (Scheme 2).
In the majority of cases though, the order of events was reversed.
Oxidation of 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine
16 yielded the corresponding sulfone 25,16 which was coupled
with a series of formamides furnishing chloro-intermediates
27a−e (Scheme 2). Final compounds 28a−e were obtained by
means of palladium-catalyzed Suzuki couplings with commer-
cially available boronic acids or esters. Pyrido[3,4-d]pyrimidines
33a and 33b were prepared by direct substitution of amines on
the 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine building
block 16 (Scheme 3). The resulting thiomethyl derivatives 29
and 30 were oxidized to the corresponding sulfones 31 and 32
and subsequently coupled with the required formamides to
aﬀord ﬁnal compounds 33a and 33b.
Pyrido[3,4-d]pyrimidines 34a−h were prepared from inter-
mediate 27a16 by displacement using the appropriate nucleo-
philes (Scheme 4). In one instance the synthetic strategy
involved the use of known pyridone 3516 as a starting material:
O-alkylation in the presence of base and bromomethyl
cyclopropane gave intermediate 36. Oxidation using m-CPBA
and subsequent coupling with formamide 26a16 aﬀorded
pyrido[3,4-d]pyrimidine 38 (Scheme 4).
In all cases, formamides and anilines were commercially
available (12, 13, 21) or could be synthesized by means of
standard transformations (22, 23,17 and 26a−e, see Exper-
Scheme 2. Synthesis of Pyrido[3,4-d]pyrimidine Derivativesa
aReagents and conditions: (a) 1-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, Na2CO3, Pd(dppf)Cl2·CH2Cl2, THF/water, 65
°C (17); (b) cyclopropyl boronic acid, K3PO4, Pd(OAc)2, PCy3, toluene/water, 95 °C (18); (c) m-CPBA, CH2Cl2, rt; (d) N-(4-
methoxyphenyl)formamide 21 or N-(2,4-dimethoxyphenyl)formamide 22, DMSO, Cs2CO3, 100 °C (24a,b); (e) 2-methoxy-4-(1-methyl-1H-
pyrazol-4-yl)aniline 23, TFA, 1,2,3-triﬂuoroethanol, μW, 130 °C (24c,d); (f) ArNHCHO (26a−e), NaH, THF, rt; (g) 1-methyl-4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole or phenyl boronic acid, Cs2CO3, Pd(PPh3)4, 1,4-dioxane/water, 100 °C. Reaction yields are in
parentheses.
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imental section and Supporting Information for details). In every
case, formylation was carried out by reﬂuxing in formic acid.
■ RESULTS AND DISCUSSION
At the start of this work, relatively few inhibitors of MPS1 had
been disclosed. In addition to our 1H-pyrrolo[3,2-c]pyridine
series,7 we had identiﬁed and crystallized 1H-pyrazolo[4,3-
c]pyridine 39, a modestly potent hit, during an initial screening
campaign. This compound showed lowmolecular weight (MW=
261) and acceptable ligand eﬃciency (L.E. = 0.43). The crystal
structure of MPS1 in complex with 39 revealed that it binds in a
complementary way to 4, whereby the pyrazole moiety binds to
the hinge region of the protein. The furan moiety occupies the
same region as the carbamate in the 1H-pyrrolo[3,2-c]pyridine
series. The phenyl ring and aniline moiety also occupy similar
parts of the binding pocket (Figure 2).18 Based on these results,
we anticipated that 39 would represent a viable starting point for
a second series but that extensive optimization of potency and
selectivity would be required. In order to rapidly discover a new
series, while utilizing previously gained SAR data, we merged the
1H-pyrrolo[3,2-c]pyridine scaﬀold with the screening hit 39
(Figure 3). Docking suggested that both the isoquinoline and
pyrido[3,4-d]pyrimidine scaﬀolds could serve as hinge-binder
elements for such a hybrid series (Figure 3). The isoquinoline
scaﬀold had the advantage that proof-of-concept molecules could
be rapidly prepared using precedented chemistry and commer-
cially available building blocks. The pyrido[3,4-d]pyrimidine
scaﬀold, on the other hand, was attractive from the point of view
of novelty, the signiﬁcantly lower lipophilicity, and the fact that it
incorporated an additional pyridine nitrogen from screening hit
39. This scaﬀold, however, required signiﬁcant investigation into
its synthesis.16 Our plan was thus to prepare a select number of
Scheme 3. Functionalization of Pyrido[3,4-d]pyrimidine Corea
aReagents and conditions: (a) Amine, NMP, 80−135 °C; (b) m-CPBA, CH2Cl2, rt; (c) 2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)aniline 23, TFA,
1,2,3-triﬂuoroethanol, μW, 130 °C. Reaction yields are in parentheses.
Scheme 4. Synthesis of Derivatives Containing 8-Position N, O, and S Substituentsa
aReagents and conditions: (a) Amine, NMP, 80−135 °C (34a−e, g, h); (b) cyclohexyl thiol, K2CO3, DMF, rt (34f); (c) Ag2CO3, bromomethyl
cyclopropane, CHCl3, rt to 60 °C; (d) m-CPBA, CH2Cl2, rt; (e) N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)formamide 26a, NaH, THF, rt.
Reaction yields are in parentheses.
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proof-of-concept molecules based on the isoquinoline core and
to expand into the less explored and more polar pyrido[3,4-
d]pyrimidine series if the initial isoquinolines showed promising
activity and ligand eﬃciency.
We used our biochemical MPS1 assay at 10 μM ATP
concentration and an in-house electrochemiluminescence Meso
Scale Discovery (MSD)-based cellular assay that measured
autophosphorylation of ectopically expressed MPS1 in HCT116
cells.7 In addition, we routinely determined selectivity against
CDK2 and Aurora A and B. We did not detect signiﬁcant activity
against either Aurora A or B throughout the series (see
Supporting Information). Furthermore, as the IC50 values of
our inhibitors approached the assay enzyme concentrations, and
thus the limit of the dynamic range of our biochemical assay, we
also determined the biochemical potency at a higher (1 mM)
ATP concentration (vide infra). As stated above, our overall goal
for this lead-ﬁnding eﬀort was to show that potent (cellular IC50
< 100 nM) and selective compounds (CDK2/MPS1 Ki ratio
>100) could be obtained which exhibit lower molecular weight
(around 450 Da) and improved ligand eﬃciency (L.E. in region
of 0.35) compared with the 1H-pyrrolo[3,2-c]pyridine series.
Moreover, our goal was to show robust activity in our PK/PD
human tumor xenograft model.
The data for the initial set of compounds are summarized in
Table 1. The MPS1 inhibition for 14 was modest (IC50 = 3.66
μM, Table 1), but replacing the furan with a pyrazole (15a) not
only lowered lipophilicity but also gave a 5-fold increase in
potency (Table 1). Moreover, incorporating an additional
methoxy group led to a signiﬁcant gain in potency, and the
IC50 of 15b reached our goal for an initial proof-of-concept
compound. As seen with the 1H-pyrrolo[3,2-c]pyridines,7 the
latter greatly improved selectivity toward CDK2. The signiﬁcant
gain in potency can be ascribed to the interaction of the aniline’s
2-methoxy substituent with a small hydrophobic pocket formed
by Lys529, Ile531, Gln541, and Cys604.7 This pocket is not
present in most other kinases including CDK2, explaining the
beneﬁcial eﬀect on kinase selectivity.
Having achieved satisfactory potency and ligand eﬃciency
(L.E. for 15b = 0.36) by merging the 1H-pyrrolo[3,2-c]pyridine
series and screening hit 39, we investigated the less lipophilic
pyrido[3,4-d]pyrimidine scaﬀold. Gratifyingly, 8-substituted 2-
anilinopyrido[3,4-d]pyrimidines proved to be more potent than
their isoquinoline counterparts, reaching the double digit
nanomolar range despite signiﬁcantly lower calculated logP
(Table 1). Isoquinoline 15b along with pyrido[3,4-d]-
pyrimidines 24a and 24b were next tested in an MSD-based
cellular assay. Both 15b and 24b showed only modest inhibition
of the autophosphorylation of ectopically expressed MPS1 in
HCT116 cells, most likely due to suboptimal biochemical
potency. In the 1H-pyrrolo[3,2-c]pyridine series, introduction of
a pyrazole substituent at the 4-position of the aniline caused a
signiﬁcant increase in biochemical and cellular potency.7
Gratifyingly, this structural modiﬁcation also resulted in a further
improvement in biochemical potency for the pyrido[3,4-
d]pyrimidine series, with compound 24c achieving a MPS1
IC50 = 0.008 μM and a cellular P-MPS1 IC50 = 0.604 μM (Table
1).
We solved the crystal structure of MPS1 in complex with
isoquinoline 15b and pyrido[3,4-d]pyrimidine 24b (Figure 4).
The two structures overlaid very well with the crystal structure of
1 (Figure 4A and B), binding to the hinge region through the
same motif as seen with the 1H-pyrrolo[3,2-c]pyridines. This
reinforced our initial hypothesis that merging the 1H-pyrrolo-
[3,2-c]pyridine series and 39 would give a suitable starting point
for an additional series of inhibitors. The aniline portion of all
compounds overlaps as well as the 5-position and 8-position
substituents of the isoquinolines and pyrido[3,4-d]pyrimidines,
Figure 2. Superimposed crystal structure of MPS1 (pale green) bound
to 1 (carbon atoms colored pink), extracted from PDB code 4C4J, onto
the structure of MPS1 (not shown) bound to 39 (carbon atoms colored
yellow), PDB code 5EHY, showing the complementary binding of the
modestly potent hit 39 and MPS1 inhibitor 1 to the hinge region of
MPS1.
Figure 3. Hybridization strategy for the development of a novel chemical series of inhibitors of MPS1, from previously reported inhibitor 1 and
screening hit 39.
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respectively, occupying the same region as the carbamate group
of 1. Of note is the diﬀerence in conformation for 15b and 24b
(Figure 4C andD). The introduction of two extra nitrogen atoms
into the aromatic ring, and thus removal of two hydrogen atoms,
results in a much more planar structure for the pyrido[3,4-
d]pyrimidine 24b. We measured the dihedral angles for both of
these compounds: isoquinoline 15b exhibits a dihedral angle of
98° and pyrido[3,4-d]pyrimidine 24b exhibits a dihedral angle of
−20° (Figure 4D). The more coplanar conformation of
pyrido[3,4-d]pyrimidines mirrors the coplanar conformation of
the carbamate function of 1 and is likely to be at least partially
responsible for the improved activity seen with the much less
lipophilic pyrido[3,4-d]pyrimidines. Based on these crystal
structures, we had conﬁdence that with further optimization
we would achieve potent and selective pyrido[3,4-d]pyrimidine
based inhibitors of MPS1.
Through our hybridization strategy and exploration of the
pyrido[3,4-d]pyrimidine scaﬀold, we had achieved a potent
inhibitor (24c, MPS1 IC50 = 0.008 μM) and for the ﬁrst time
reached signiﬁcant levels of cellular inhibition with IC50 values
below 1 μM. Compound 24c represented a promising starting
point for further optimization of this compound into a novel
series of MPS1 inhibitors.
Since our initial goal was to show target modulation in a
human tumor xenograft model in mice, we investigated the
stability of 24c in mouse liver microsomes. Unfortunately, 24c
showed high turnover (MLM = 73% following 30 min
incubation) and was not suitable for in vivo experiments.
Metabolite ID studies suggested loss of a methyl group, and we
suspected that the methoxy aniline substituent was the most
likely site of demethylation. This methoxy group was important
for both potency and selectivity. After consideration of the X-ray
crystal structures we had in hand, suggesting that larger
substituents at this position would be tolerated, we prepared
and tested a series of compounds in which this putative metabolic
soft spot was replaced with similar moieties (Table 2). The
majority of these compounds showed higher IC50 values than 24c
with the exception of the ethoxy derivative 28c, which achieved
comparable potency, while exhibiting signiﬁcantly improved
CDK2 selectivity (>28 fold improvement over 24c) and MLM
stability (MLM= 45%). This increase in selectivity is likely due to
the fact that the aniline 2-position substituent occupies a small
lipophilic pocket present in MPS1, mentioned previously,
consisting of Lys529, Ile531, Gln541 and the gatekeeper+2
residue Cys604. This pocket is not available in CDK2 due to the
presence of the bulkier gatekeeper residue Phe82. The larger 2-
Table 1. Biochemical and Cellular Data for Initial Proof-of-Concept Isoquinolines (14, 15a, 15b) and Pyrido[3,4-d]pyrimidines
(24a−c)a
aResults are mean (±SD) for n ≥ 3 or mean values of two independent determinations with individual determinations in parentheses or samples run
n = 1. “P-MPS1″ indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed
MPS1 in HCT116 cells. bPotency at the lower limit of the dynamic range of the Caliper assay run at 10 μM ATP concentration. IC50 value is likely
to be lower than that quoted.
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position ethoxy substituent (28c) clashes with the CDK2
gatekeeper+2 residue, resulting in a better selectivity window
than is seen for the methoxy derivative 24c.
Unfortunately, 28c was 5-fold less active in the cellular assay,
which given the similar biochemical potency and physicochem-
ical properties was diﬃcult to rationalize. While we regarded the
ethoxy as a valuable alternative for the methoxy group, with
signiﬁcantly improved selectivity and reduced risk of reactive
intermediate formation through metabolic dealkylation, we
decided to maintain the methoxy in place due to the improved
cellular activity. Instead, we looked to improve the metabolic
stability through modiﬁcation at the 8-position of the pyrido[3,4-
d]pyrimidine scaﬀold. We hypothesized that by introducing
diverse substituents at this position of the scaﬀold, the molecular
recognition of the compounds by metabolic enzymes would be
aﬀected leading to increased stability.
In order to address these aspects we used the structural
information gathered on pyrido[3,4-d]pyrimidine 24c. The
crystal structure of this inhibitor showed that the 8-position
pyrazole group binds to a hydrophobic pocket formed by Ile531,
Val539, Met671, and Pro673 (Figure 5A). This is the same
pocket that is occupied by the carbamate group of 1 and is
suﬃciently large to accommodate a variety of hydrophobic
groups (Figure 5B). It is also of note that the crystal structure of
MPS1 in complex with 24c shows ordering of the activation loop
of MPS1, as is seen with 1.7 We thus prepared and tested a small
set of compounds with diﬀerent pyrazole replacements including
a saturated pyrrolidine ring.
The data for these compounds are summarized in Table 3. The
phenyl-substituted derivative (28a) showed comparable potency
in the biochemical and cellular assay and, despite higher
lipophilicity, improved microsomal stability. The cyclopropyl
derivative 24d lost considerable activity, possibly due to the fact
that this group is too small to engage in signiﬁcant hydrophobic
interactions. Interestingly, replacement of the pyrazole with a
saturated pyrrolidine (33a) led to an equipotent compound in
the biochemical assay. All compounds showed selectivity against
CDK2 (CDK2/MPS1 ratio >80).
Of the compounds presented in Table 3, we considered the
pyrrolidine derivative (33a) as the most promising for further
optimization. A saturated moiety oﬀered more possibilities to
optimize the three-dimensional hydrophobic interactions in this
subpocket compared with an aromatic ring where substituents
can only be placed in the plane of the ring. Furthermore,
increasing the number of sp3 centers has been suggested as a
general approach to improve solubility and drug-like proper-
ties.19 We thus prepared a series of compounds with a saturated
substituent in this position.
Importantly, since the IC50 values of many compounds were
now approaching the enzyme concentration and thus the limit of
the dynamic range of the biochemical assay, we complemented
the MPS1 kinase assay at 10 μMATP with testing at 1 mM ATP.
It has been demonstrated that increasing the ATP concentration
shifts the IC50 values of ATP competitive inhibitors to higher
values, therefore increasing the dynamic range of the assay.20 Due
to the diﬀering ATP concentrations in the high ATP Caliper
assay and the CDK2 assay (1 mM MPS1 vs 10 μM CDK2), the
assays were no longer directly comparable. For this reason, we
used the Cheng−Prusoﬀ equation to calculate the Ki values
21
and, in turn, used these values to determine the selectivity
window.
Compound 33b, incorporating a diethylamine substituent,
was signiﬁcantly (6-fold) less potent in the 1 mM ATP Caliper
assay than the pyrrolidine 33a (Table 4). This is likely due to a
Figure 4. (A) Superimposed crystal structure of MPS1 (pale green) bound to 1 (carbon atoms colored pink), extracted from PDB code 4C4J, onto the
structure of MPS1 (not shown) bound to 15b (carbon atoms colored cyan), PDB code 5EI6. (B) Superimposed crystal structure of MPS1 (pale green)
bound to 1 (carbon atoms colored pink), extracted from PDB code 4C4J, onto the structure of MPS1 (not shown) bound to 24b (carbons atoms
colored green), PDB code 5EI2. (C) Superimposed crystal structure of MPS1 (pale green) bound to 15b (carbon atoms colored cyan), extracted from
PDB code 5EI6, onto the structure of MPS1 (not shown) bound to 24b (carbon atoms colored green), PDB code 5EI2, showing the extent of the
conformational diﬀerence between the isoquinoline and pyrido[3,4-d]pyrimidine scaﬀolds. (D) Side-by-side view of compound 15b (carbon atoms
colored cyan) and 24b (carbon atoms colored green) showing the diﬀerence in angle of theN-methylpyrazole group. 2Fo− Fc density contoured at 1σ
is overlaid and displayed in the same color as the respective compound carbon atom color. A water molecule interacting with compound 24b is also
displayed as a red sphere. 15b exhibits a dihedral angle of 98°, and 24b exhibits a dihedral angle of −20°.
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higher free energy penalty when binding to the target for this less
constrained compound. Gratifyingly, several amine substituents
(34b, d, and e) not only showed comparable biochemical
potency but also improved microsomal stability, now in an
acceptable range of 30% turnover.
Since saturated amines were well tolerated in this position, we
next prepared and tested derivatives in which the alkyl groups
were linked through a sulfur or oxygen atom (34f and 38).
Remarkably, both lost signiﬁcant activity (at least 10-fold)
compared to the corresponding amine derivatives 34b and 34d.
It is diﬃcult to reconcile the pronounced loss of activity of
compounds 34f and 38 with the wide range of both primary and
secondary amines that are tolerated. Computational conforma-
tional analysis did not suggest a signiﬁcant diﬀerence in the
conformational preference of the oxygen and sulfur-linked
substituents compared to the amine substituents. Furthermore,
analysis of the available crystal structure did not support the
hypothesis that this diﬀerence may be driven by diﬀerent
hydrogen-bond pattern, e.g., to water molecules.
Several amino-substituted compounds did however show
potent IC50 values suggesting signiﬁcant scope for further
modiﬁcations. The neopentyl derivative 34e was particularly
promising due to its cellular potency combined with selectivity
and improved mouse microsomal stability. As is apparent from
the MPS1 IC50 at 1 mM ATP, it was also the most potent
derivative in this series.
Table 2. Biochemical, Cellular, AndMouse Microsomal Turnover Data for Compounds Bearing Alternative Aniline Substituentsa
aResults are mean (±SD) for n ≥ 3, or mean values of two independent determinations with individual determinations in parentheses or samples run
n = 1. “P-MPS1″ indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed
MPS1 in HCT116 cells. bPotency at the lower limit of the dynamic range of the Caliper assay run at 10 μM ATP concentration. IC50 value is likely
to be lower than that quoted.
Figure 5. (A) Crystal structure of MPS1 (pale green) bound to 24c
(carbon atoms colored orange), extracted from PDB code 5EI8,
showing residues (Ile531, Val539, Met671, and Pro673) present in the
hydrophobic pocket occupied by 8-position pyrazole. (B) Super-
imposed crystal structure of MPS1 (pale green) bound to 24c (carbon
atoms colored orange), extracted from PDB code 5EI8, onto the
structure of MPS1 (not shown) bound to 1 (carbon atoms colored
pink), PDB code 4C4J, showing that this is the same pocket occupied by
the carbamate group of 1 (carbon atoms colored pink).
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We solved the structure of neopentyl 34e bound into MPS1
(Figure 6). Figure 6 shows that the bulkier, more hydrophobic
neopentyl substituent of 34e addresses the hydrophobic pocket
ﬁrst mentioned in Figure 5A to a greater extent than the pyrazole
substituent of 24c. We hypothesized that an additional increase
in potency could be achieved by further increasing the bulk of the
hydrophobic substituent.
We thus followed up by synthesizing the two enantiomers 34g
and 34h which diﬀer from the neopentyl 34e by an additional
methyl group (Table 5). The (S)-enantiomer (34h) particularly,
translated into an additional gain in biochemical and cellular
potency compared with neopentyl derivative 34e, achieving
cellular modulation of MPS1 in the sub-100 nM range (Table 5).
34h showed suﬃcient selectivity over CDK2 and very good
microsomal stability (MLM = 27%).
With 34h we had achieved our initial potency goal in the
biochemical and cellular assay. Especially considering its
moderate molecular weight of 432 Da, 34h represented an
extremely potent MPS1 inhibitor with an IC50 = 0.020 μM at 1
mM ATP (corresponding to a Ki of 0.0002 μM)
21 and a GI50
value in HCT116 cells of 0.16 μM. Furthermore, the combined
SAR suggested signiﬁcant scope for additional modiﬁcations to
further optimize the series. This pyrido[3,4-d]pyrimidine (34h)
was selective over CDK2 (CDK2/MPS1 Ki ratio > 1000),
21
Aurora A and B (Table S1 ), and PLK1 (IC50 > 100 μM) as well
as against a wide panel of kinases (Tables S2−S4 ). Pyrido[3,4-
d]pyrimidine 34h inhibited a small number of kinases, namely
TNK2, JNK1, JNK2, and LRRK at >80% at 1 μM. JNK1 and
JNK2 are considered to be structurally related toMPS1, so follow
up IC50 values were obtained (JNK1 IC50 = 0.11 μM, JNK2 IC50
= 0.22 μM), showing that 34hwas selective for MPS1 over JNK1
and JNK2 by 100- and 200-fold, respectively.
Next we proﬁled 34h against a panel of cell lines (Table 6). As
expected for an MPS1 inhibitor, 34h showed potent growth
inhibition for all cancer cell lines but importantly a signiﬁcantly
higher GI50 for the nontransformed line PNT2.
34h did not inhibit CYP or hERG (Tables S5 and S6).
Importantly, pyrido[3,4-d]pyrimidine 34h, showed low turnover
in mouse and rat liver microsomes (27 and 24%, after 30 min
incubation, respectively), and we progressed the compound to
mouse and rat PK experiments, despite a 70% turnover in human
liver microsomes, in order to evaluate its suitability for proof of
mechanism in vivo experiments. 34h showedmoderate clearance
(28 and 24 mL/min/kg in mouse and rat, respectively) and high
oral bioavailability (68 and 100% in mouse and rat, respectively)
with moderate to high volumes of distribution (Table 7).
We thus performed a 3 day pharmacokinetic/pharmacody-
namic (PK/PD) study to determine whether biomarker
modulation could be achieved in vivo. MPS1 inhibition results
in premature exit of cells frommitosis,10e and we therefore chose
themitotic marker phospho-histoneH3 as a readout. HistoneH3
is speciﬁcally phosphorylated at Ser 10 during mitosis.22
Gratifyingly, oral administration of 100 mg/kg of 34h b.i.d. for
3 days to mice bearing HCT116 human colon carcinoma
xenografts caused a reduction of the phospho-histone H3 levels
compared with vehicle control treated animals at 2 and 6 h,
consistent with MPS1 inhibition (Figure 7).
Compound 34h fulﬁlled all of the criteria we had initially set
and compared favorably with our best-in-class 1H-pyrrolo[3,2-
c]pyridine (1). Particularly, 34h was devoid of CYP inhibition,
did not require an acid labile Boc group for biochemical and
Table 3. Biochemical, Cellular, And Mouse Microsomal Turnover Data for Compounds Bearing Alternative 8-Position
Substituentsa
aResults are mean (±SD) for n ≥ 3, or mean values of two independent determinations with individual determinations in parentheses or samples run
n = 1. “P-MPS1″ indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed
MPS1 in HCT116 cells. bPotency at the lower limit of the dynamic range of the Caliper assay run at 10 μM ATP concentration. IC50 value is likely
to be lower than that quoted.
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cellular potency, and showed excellent overall selectivity. Its
physicochemical properties (ALogP = 4.65 and MW = 432)
made 34h a better starting point for further optimization
especially given that we had already achieved the targeted
potency. Surprisingly, given that it represented a pyrimidine-
based kinase scaﬀold, the 2-amino pyrido[3,4-d]pyrimidine
chemotype was relatively unexplored when we initiated this
work, with only one published kinase patent application in the
public domain.23 Our previously published chemical route16
facilitated the synthesis of a large range of derivatives as well as
upscaling of advanced derivatives. We thus nominated 34h as an
advanced lead compound.
Table 4. Biochemical, Cellular, And Mouse Microsomal Turnover Data for Compounds Bearing a Saturated Substituent at the 8-
Positiona
aResults are mean (±SD) for n ≥ 3, or mean values of two independent determinations with individual determinations in parentheses or samples run
n = 1. “P-MPS1″ indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed
MPS1 in HCT116 cells. “HCT116 GI50” indicates a cell proliferation assay carried out by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay in HCT116 cells. bPotency at the lower limit of the dynamic range of the Caliper assay run at 10 μM
ATP concentration. IC50 value is likely to be lower than that quoted.
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■ CONCLUSIONS
By merging two distinct chemical series, namely 1H-pyrrolo[3,2-
c]pyridines and 1H-pyrazolo[4,3-c]pyridines, we successfully
fulﬁlled our aim to discover a new class of MPS1 inhibitors that
did not require an acid labile Boc group for potent inhibition.
The pyrido[3,4-d]pyrimidine core was unprecedented for
kinases,16 and our structure guided optimization resulted in
potent MPS1 inhibitors of substantially reduced size and
lipophilicity compared with the parent 1H-pyrrolo[3,2-c]-
pyridines. Moreover, our optimized compound 34h was devoid
of CYP inhibition and proved to be extremely potent in the
MPS1 biochemical assay with the ability to target this kinase in
cells and to induce signiﬁcant growth inhibition at nanomolar
concentrations. A screen against a large sample of the human
kinome revealed a high level of selectivity, especially with regard
to mitotic kinases. Most importantly, pyrido[3,4-d]pyrimidine
34h showed a satisfactory pharmacokinetic proﬁle in rodents and
eﬀectively inhibited MPS1 activity in vivo.
Optimization of the remaining issues associated with 34h, in
particular HLM instability and plasma protein binding, as well as
the investigation of advanced compounds in combination
eﬃcacy models, is ongoing and the results will be reported in
due course.
Figure 6. Superimposed crystal structure of MPS1 (pale green) bound
to 24c (carbon atoms colored orange), extracted from PDB code 5EI8,
onto the structure of MPS1 (not shown) bound to 34e (carbon atoms
colored blue), PDB code 5EH0, showing the hydrophobic pocket
formed by Ile531, Val539, Met671, and Pro673. The bulkier neopentyl
substituent of 34e addresses the pocket to a greater extent than the
pyrazole substituent of 24c.
Table 5. Biochemical, Cellular, And Mouse Microsomal Turnover Data for Enantiomers 34g and 34ha
aResults are mean (±SD) for n ≥ 3, or mean values of two independent determinations with individual determinations in parentheses or samples run
n = 1. “P-MPS1″ indicates an electrochemiluminescence MSD-based cellular assay that measured autophosphorylation of ectopically expressed
MPS1 in HCT116 cells. “HCT116 GI50” indicates a cell proliferation assay carried out by colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay in HCT116 cells. bPotency at the lower limit of the dynamic range of the Caliper assay run at 10 μM
ATP concentration. IC50 value is likely to be lower than that quoted.
Table 6. GI50 Values for 34h in 3 Day MTT Assay Carried out
on Panel of Cell Linesa
origin cell line GI50 (μM)
colon SW620 0.065
head and neck CAL27 0.23
breast CAL51 0.068
pancreatic Miapaca-2 0.25
ovarian RMG1 0.110
prostate PNT2 3.95
a“GI50” indicates a cell proliferation assay carried out by colorimetric
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay in a panel of cell lines.
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■ EXPERIMENTAL SECTION
General Chemistry Information. Starting materials, reagents, and
solvents for reactions were reagent grade and used as purchased.
Chromatography solvents were HPLC grade and were used without
further puriﬁcation. Thin-layer chromatography analysis was performed
using silica gel 60 F-254 thin-layer plates. Flash column chromatography
was carried out using columns prepacked with 40−63 μm silica.
Microwave-assisted reactions were carried out using a Biotage Initiator
microwave system. LCMS and HRMS analyses were performed on a
HPLC system with diode array detector operating at 254 nm, ﬁtted with
a reverse-phase 50 × 4.6 mm column at a temperature of 22 °C,
connected to a time of ﬂight mass spectrometer (ESI). The following
solvent system, at a ﬂow rate of 2 mL/min, was used: Solvent A:
methanol; solvent B: 0.1% formic acid in water. Gradient elution was as
follows: 1:9 (A:B) to 9:1 (A:B) over 2.5 min, 9:1 (A:B) for 1 min then
reversion back to 1:9 (A:B) over 0.3 min, 1:9 (A:B) for 0.2 min. 1H
NMR spectra were recorded on a Bruker Avance 500MHz spectrometer
using an internal deuterium lock. NMR data is given as follows: chemical
shift (δ) in ppm, multiplicity, coupling constants (J) given in Hz and
integration. The purity of ﬁnal compounds was determined by HPLC as
described above and is ≥95% unless speciﬁed otherwise.
Compounds 2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)aniline (23),17
8-chloro-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine (25),16 N-(2-me-
thoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)formamide (26a),16 8-
chloro-N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-
d]pyrimidin-2-amine (27a),16 and 2-(methylthio)pyrido[3,4-d]-
pyrimidin-8(7H)-one (35)16 were synthesized using previously
published procedures.
3-Chloro-5-(furan-2-yl)isoquinoline 10. A suspension of 5-bromo-
3-chloroisoquinoline 9 (58 mg, 0.24 mmol), furan-2-ylboronic acid (32
mg, 0.29 mmol), and Pd(dppf)Cl2·CH2Cl2 (20 mg, 0.024 mmol) in
DME (0.5mL) and sodium carbonate (2M, 0.24mL) was heated to 105
°C under microwave irradiation for 1 h. The mixture was concentrated
onto silica gel and puriﬁed by ﬂash column chromatography (0−50%
EtOAc in cyclohexane) to give the title compound (41 mg, 75%).
HRMS (ESI) m/z calcd for C13H9ClNO (M + H) 230.0367, found
230.0343. 1H NMR (500 MHz, CDCl3) δ 9.09 (s, 1H), 8.33 (s, 1H),
7.99−7.90 (m, 2H), 7.71−7.55 (m, 2H), 6.79 (dd, J = 3.4, 0.6 Hz, 1H),
6.62 (dd, J = 3.4, 1.8 Hz, 1H).
3-Chloro-5-(1-methyl-1H-pyrazol-4-yl)isoquinoline 11. A suspen-
sion of 5-bromo-3-chloroisoquinoline 9 (300 mg, 1.24 mmol), 1-
methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(309 mg, 1.49 mmol), and Pd(dppf)Cl2·CH2Cl2 (105 mg, 0.124 mmol)
in DME (2.5 mL) and sodium carbonate (2 M, 1.24 mL) was heated to
105 °C under microwave irradiation for 1.5 h. The mixture was
concentrated onto silica gel and puriﬁed by ﬂash column chromatog-
raphy (0−100% EtOAc in cyclohexane) to give the title compound (324
mg, quant.). HRMS (ESI) m/z calcd for C13H11ClN3 (M + H)
244.0636, found 244.0639. 1H NMR (500MHz, CDCl3) δ 9.08 (s, 1H),
7.96 (s, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.73 (s, 1H), 7.67−7.55 (m, 3H),
4.05 (s, 3H).
5-(Furan-2-yl)-N-(4-methoxyphenyl)isoquinolin-3-amine 14. A
suspension of 3-chloro-5-(furan-2-yl)isoquinoline 10 (41 mg, 0.18
mmol), 4-methoxyaniline 12 (29 mg, 0.23 mmol), cesium carbonate
(204 mg, 0.626 mmol), tBuXPhos (30 mg, 0.071 mmol), Pd2(dba)3 (16
mg, 0.018 mmol), and tBuOH (3% H2O) (1 mL) was heated to 80 °C
under microwave irradiation for 3 h. The mixture was concentrated onto
silica gel and puriﬁed by ﬂash column chromatography (0−100% EtOAc
in cyclohexane) to give the title compound (10 mg, 18%). HRMS (ESI)
m/z calcd for C20H17N2O2 (M + H) 317.1285, found 317.1282.
1H
NMR (500 MHz, CDCl3) δ 8.95 (s, 1H), 7.84−7.75 (m, 2H), 7.61 (s,
1H), 7.57 (s, 1H), 7.58−7.25 (m, 3H), 7.17−6.90 (m, 2H), 6.77−6.60
(m, 2H), 6.54 (dd, J = 3.3, 1.8 Hz, 1H), 3.85 (s, 3H).
N-(4-Methoxyphenyl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-
amine 15a. A suspension of 3-chloro-5-(1-methyl-1H-pyrazol-4-
yl)isoquinoline 11 (55 mg, 0.23 mmol), 4-methoxyaniline 12 (36 mg,
0.29 mmol), cesium carbonate (257 mg, 0.789 mmol), tBuXPhos (38
mg, 0.090 mmol), Pd2(dba)3 (21 mg, 0.023 mmol), and
tBuOH (3%
H2O) (1mL) was heated to 80 °C under microwave irradiation for 1.5 h.
The mixture was concentrated onto silica gel and puriﬁed by ﬂash
column chromatography (0−100% EtOAc in cyclohexane) to give the
title compound (6 mg, 8%). HRMS (ESI)m/z calcd for C20H19N4O (M
+H) 331.1553, found 331.1546. 1HNMR (500MHz, CDCl3) δ 8.95 (s,
1H), 7.75 (d, J = 8.2 Hz, 1H), 7.68 (s, 1H), 7.52 (s, 1H), 7.50−7.46 (m,
Table 7. Mouse and Rat Blood Pharmacokinetics of 34h at 5 mg/kg iv and po
species t1/2 (h) Cl (mL/min/kg) Cmaxpo (nmol/L) AUCpo (nmol·h/L) PPB (%) Vss (L/kg) F (%)
mouse 8.2 28 770 4800 99.98 14.7 68
rat 2.5a 24 560 9300 99.97 4.64 100
aOnly detected to 4 h.
Figure 7. (A,B) Representative immunoblots of phospho-histone H3 showing dose-dependent PD modulation in HCT116 human tumor xenografts,
following 100 mg/kg b.i.d. dosing of 34h for 3 consecutive days. Total histone H3, cleaved poly ADP ribose polymerase (PARP, a measure of apoptosis)
and glyceraldehyde 3-phosphate dehydrogenase (GADPH, for protein loading) are also shown. (C) Phospho-histone H3 versus total histone H3 ratio
for control and treated samples at 2 and 6 h after last dose. Asterisks show statistically signiﬁcant diﬀerences from control groups as determined by one-
way ANOVA.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.5b01811
J. Med. Chem. 2016, 59, 3671−3688
3682
2H), 7.31−7.21 (m, 3H), 7.03−6.89 (m, 2H), 6.48 (s, 1H), 3.98 (s, 3H),
3.83 (s, 3H).
N-(2,4-Dimethoxyphenyl)-5-(1-methyl-1H-pyrazol-4-yl)-
isoquinolin-3-amine 15b. A suspension of 3-chloro-5-(1-methyl-1H-
pyrazol-4-yl)isoquinoline 11 (55 mg, 0.23 mmol), 2,4-dimethoxyaniline
13 (45 mg, 0.29 mmol), cesium carbonate (257 mg, 0.789 mmol),
tBuXPhos (38 mg, 0.090 mmol), Pd2(dba)3 (21 mg, 0.023 mmol), and
tBuOH (3% H2O) (1 mL) was heated to 80 °C under microwave
irradiation for 1.5 h and then to 100 °C for 1.5 h. The mixture was
concentrated onto silica gel and puriﬁed by ﬂash column chromatog-
raphy (0−100% EtOAc in cyclohexane) to give the title compound (22
mg, 27%). HRMS (ESI) m/z calcd for C21H21N4O2 (M + H) 361.1659,
found 361.1661. 1HNMR (500MHz, CDCl3) δ 8.96 (s, 1H), 7.78−7.69
(m, 2H), 7.61 (d, J = 8.6 Hz, 1H), 7.54 (s, 1H), 7.47 (dd, J = 7.0, 1.0 Hz,
1H), 7.33−7.23 (m, 2H), 6.73 (s, 1H), 6.58−6.49 (m, 2H), 3.99 (s, 3H),
3.85 (s, 3H), 3.83 (s, 3H).
Preparation of Compounds in Scheme 2 (Exempliﬁed by the
Preparation of Compounds 24a, 24d, 28a, and 28b). 8-(1-Methyl-
1H-pyrazol-4-yl)-2-(methylthio)pyrido[3,4-d]pyrimidine 17. A solu-
tion of 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine 16 (480 mg,
2.27 mmol), (1-methyl-1H-pyrazol-4-yl)boronic acid pinacol ester (940
mg, 4.52 mmol), and Pd(dppf)Cl2·CH2Cl2 (100 mg, 0.122 mmol) in
THF (15 mL) and sodium carbonate (2 M, 5 mL) was heated to 65 °C
for 18 h. The mixture was diluted with EtOAc and quenched with brine.
The aqueous layer was extracted with EtOAc three times. The combined
organics were washed with water and brine, dried, and concentrated in
vacuo. The residue was puriﬁed by ﬂash column chromatography (0−
4% MeOH in CH2Cl2) to give the title compound (658 mg, quant).
HRMS (ESI) m/z calcd for C12H12N5S (M + H) 258.0813, found
258.0817. 1H NMR (500 MHz, CDCl3) δ 9.22 (s, 1H), 8.67 (s, 1H),
8.63−8.56 (m, 2H), 7.47 (d, J = 5.3 Hz, 1H), 4.05 (s, 3H), 2.78 (s, 3H).
8-Cyclopropyl-2-(methylthio)pyrido[3,4-d]pyrimidine 18. A solu-
tion of 8-chloro-2-(methylthio)pyrido[3,4-d]pyrimidine 16 (20 mg,
0.094 mmol), cyclopropyl boronic acid (11 mg, 0.13 mmol), PCy3 (3
mg, 11 μmol), K3PO4 (70 mg, 0.32 mmol), and Pd(OAc)2 (1.0 mg, 4.5
μmol) was dissolved in toluene/water (6:1, 1 mL) and heated to 95 °C
for 18 h. The mixture was diluted with EtOAc and quenched with brine.
The aqueous layer was extracted with EtOAc three times. The combined
organics were washed with water and brine, dried, and concentrated in
vacuo. The residue was puriﬁed by ﬂash column chromatography (0−
20% EtOAc in cyclohexane) to give the title compound (13 mg, 62%).
HRMS (ESI)m/z calcd C11H12N3S (M+H) 218.0746, found 218.0751.
1H NMR (500 MHz, CDCl3) δ 9.18 (s, 1H), 8.46 (d, J = 5.4 Hz, 1H),
7.37 (d, J = 5.5Hz, 1H), 3.46 (tt, J = 8.2, 4.8 Hz, 1H), 2.74 (s, 3H), 1.34−
1.27 (m, 2H), 1.25−1.17 (m, 2H).
8-(1-Methyl-1H-pyrazol-4-yl)-2-(methylsulfonyl)pyrido[3,4-d]-
pyrimidine 19. A suspension of 8-(1-methyl-1H-pyrazol-4-yl)-2-
(methylthio)pyrido[3,4-d]pyrimidine 17 (584 mg, 2.27 mmol) in
CH2Cl2 (22 mL) was treated with m-CPBA (77% w/w, 1.12 g, 4.98
mmol) at 0 °C and then allowed to reach rt over 18 h. The mixture was
quenched with water and extracted with CH2Cl2. The combined
organics were washed with water, dried, and concentrated in vacuo. The
residue was puriﬁed by ﬂash column chromatography (0−100% EtOAc
in cyclohexane) to give the title compound (408 mg, 62%). HRMS
(ESI) m/z calcd for C12H12N5O2S (M + H) 290.0706, found 290.0722.
1H NMR (500 MHz, (CD3)2SO) δ 10.00 (s, 1H), 8.91 (d, J = 5.4 Hz,
1H), 8.81 (s, 1H), 8.53 (s, 1H), 7.99 (d, J = 5.4 Hz, 1H), 3.99 (s, 3H),
3.59 (s, 3H).
8-Cyclopropyl-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine 20. A
suspension of 8-cyclopropyl-2-(methylthio)pyrido[3,4-d]pyrimidine
18 (127 mg, 0.584 mmol) in CH2Cl2 (5 mL) was treated with m-
CPBA (77%w/w, 290mg, 1.29mmol) at 0 °C and then allowed to reach
rt over 18 h. The mixture was quenched with water and extracted with
CH2Cl2. The combined organics were washed with water, dried, and
concentrated onto silica. The residue was puriﬁed by ﬂash column
chromatography (0−70% EtOAc in cyclohexane) to give the title
compound (128 mg, 88%). HRMS (ESI)m/z calcd C11H12N3O2S (M +
H) 250.0645, found 250.0648. 1H NMR (500 MHz, (CD3)2SO) δ 9.99
(s, 1H), 8.79 (d, J = 5.5 Hz, 1H), 7.94 (d, J = 5.5 Hz, 1H), 3.56 (s, 3H),
3.44 (m, 1H), 1.30−1.25 (m, 2H), 1.24−1.20 (m, 2H).
N-(4-Methoxyphenyl)-8-(1-methyl-1H-pyrazol-4-yl)pyrido[3,4-d]-
pyrimidin-2-amine 24a. To a solution of 8-(1-methyl-1H-pyrazol-4-
yl)-2-(methylsulfonyl)pyrido[3,4-d]pyrimidine 19 (29 mg, 0.10 mmol)
in DMSO (4 mL) was added cesium carbonate (59 mg, 0.18 mmol) and
N-(4-methoxyphenyl)formamide (15 mg, 0.10 mmol). The mixture was
heated to 100 °C for 18 h. The mixture was diluted with EtOAc and
water. The aqueous layer was re-extracted with EtOAc. The combined
organics were washed with brine, dried, and concentrated in vacuo. The
residue was puriﬁed by ﬂash column chromatography (0−10% MeOH
in CH2Cl2), followed by SCX-2 cartridge (MeOH - 1MNH3 inMeOH)
to give the title compound (8 mg, 24%). HRMS (ESI) m/z calcd
C18H16N6O (M + H) 333.1464, found 333.1450.
1H NMR (500 MHz,
CD3OD) δ 9.24 (s, 1H), 8.38 (s, 1H), 8.29 (d, J = 5.4 Hz, 1H), 7.63−
7.59 (m, 3H), 7.54 (d, J = 5.4 Hz, 1H), 7.05 (d, J = 8.9 Hz, 2H), 3.91 (s,
3H), 3.87 (s, 3H).
8-Cyclopropyl-N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)-
phenyl)pyrido[3,4-d]pyrimidin-2-amine 24d. A solution of 2-
methoxy-4-(1-methyl-1H-pyrazol-4-yl)aniline 23 (50 mg, 0.25 mmol),
TFA (45 μL, 0.60 mmol), and 8-cyclopropyl-2-(methylsulfonyl)pyrido-
[3,4-d]pyrimidine 20 (31 mg, 0.12 mmol) in 2,2,2-triﬂuoroethanol (0.7
mL) was heated to 130 °C under microwave irradiation for 1.5 h. The
reaction was diluted with EtOAc and quenched with aqueous sat.
sodium bicarbonate. The aqueous layer was extracted with EtOAc, and
the combined organics were washed with water and brine, dried, and
concentrated in vacuo. The residue was puriﬁed by ﬂash column
chromatography (0−60% EtOAc in cyclohexane) to give the title
compound (20 mg, 43%). HRMS (ESI)m/z calcd for C21H21N6O (M +
H) 373.1771, found 373.1773. 1H NMR (500 MHz, (CD3)2SO) δ 9.40
(s, 1H), 8.54 (s, 1H), 8.41 (d, J = 8.3 Hz, 1H), 8.28 (d, J = 5.3 Hz, 1H),
8.17 (d, J = 0.9 Hz, 1H), 7.90 (d, J = 0.8 Hz, 1H), 7.56 (d, J = 5.3 Hz,
1H), 7.30 (d, J = 1.8 Hz, 1H), 7.25 (dd, J = 8.2, 1.8 Hz, 1H), 3.96 (s, 3H),
3.88 (s, 3H), 3.24 (m, 1H), 1.16−1.08 (m, 4H).
Preparation of Formamides 26b−e (Exempliﬁed by Prepara-
tion of Compound 26b). N-(2-Methyl-4-(1-methyl-1H-pyrazol-4-
yl)phenyl)formamide 26b. A solution of 2-methyl-4-(1-methyl-1H-
pyrazol-4-yl)aniline S1 (100mg, 0.534mmol) in formic acid (3mL) was
heated to 100 °C for 3 h. The mixture was concentrated in vacuo. The
residue was partitioned between aqueous sat. sodium bicarbonate and
EtOAc. The aqueous layer was re-extracted with EtOAc. The combined
organics were washed with water and brine, dried, and concentrated in
vacuo. The residue was puriﬁed by ﬂash column chromatography (0−
10% MeOH in EtOAc) to give the title compound (160 mg, 34%).
HRMS (ESI) m/z calcd for C12H14N3O (M + H) 216.1131, found
216.1141. 1H NMR (500 MHz, CD3OD) δ 8.31 (s, 1H), 7.93 (s, 1H),
7.80 (s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 2.0Hz, 1H), 7.38 (dd, J
= 8.0, 2.0, Hz, 1H), 3.92 (s, 3H), 2.31 (s, 3H).
8-Chloro-N-(2-methyl-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-
pyrido[3,4-d]pyrimidin-2-amine 27b. To a cooled (0 °C) suspension
of N-(2-methyl-4-(1-methyl-1H-pyrazol-4-yl)phenyl)formamide 26b
(40 mg, 0.19 mmol) in THF (4 mL) was added sodium hydride (60%
w/w dispersion in oil, 12 mg, 0.30 mmol). The reaction mixture was
stirred at rt for 10 min. The mixture was cooled to 0 °C, and 8-chloro-2-
(methylthio)pyrido[3,4-d]pyrimidine 2516 (60 mg, 0.24 mmol) was
added. The mixture was stirred for 18 h while slowly warming to rt and
then concentrated in vacuo, and the residue was partitioned between
EtOAc and water. The aqueous layer was extracted with EtOAc and
CH2Cl2. The combined organics were washed with water and brine,
dried, and concentrated in vacuo. The residue was puriﬁed by ﬂash
column chromatography (0−5% MeOH in EtOAc) to give the title
compound (79mg, 97%). HRMS (ESI)m/z calcd for C19H16ClN6 (M +
H) 351.1119, found 351.1111. 1H NMR (500 MHz, CDCl3) δ 9.17 (s,
1H), 8.26 (d, J = 5.0 Hz, 1H), 7.79 (s, 1H), 7.63 (s, 1H), 7.52 (d, J = 5.0
Hz, 1H), 7.47 (dd, J = 8.0, 2.0 Hz, 1H), 7.42 (m, 1H), 7.39 (d, J = 2.0 Hz,
1H), 3.98 (s, 3H), 2.44 (s, 3H).
N-(2-Methoxy-4-(1-methyl-1H-pyrazol-4-yl )phenyl)-8-
phenylpyrido[3,4-d]pyrimidin-2-amine 28a. To a solution of 8-
chloro-N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-
d]pyrimidin-2-amine 27a16 (25 mg, 0.068 mmol) in 1,4-dioxane/water
(2:1, 3 mL) was added phenyl boronic acid (17 mg, 0.14 mmol),
Pd(PPh3)4 (16 mg, 0.014 mmol), and cesium carbonate (33 mg, 0.10
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mmol). The reaction was heated to 100 °C under microwave irradiation
for 30 min. The reaction was diluted with EtOAc and water, dried, and
concentrated in vacuo. The residue was puriﬁed by ﬂash column
chromatography (0−100% EtOAc in cyclohexane) followed by SCX-2
cartridge (MeOH - 1 M NH3 in MeOH) to give the title compound (8
mg, 29%). HRMS (ESI) m/z calcd for C24H21N6O (M + H) 409.1777,
found 409.1771. 1HNMR (500MHz, CD3OD) δ 9.37 (s, 1H), 8.56 (d, J
= 8.5Hz, 1H), 8.50 (d, J = 5.5Hz, 1H), 8.11−8.09 (m, 2H), 7.97 (s, 1H),
7.82 (s, 1H), 7.79 (d, J = 5.5Hz, 1H), 7.61−7.59 (m, 3H), 7.19 (d, J = 2.0
Hz, 1H), 6.99 (dd, J = 8.5, 2.0 Hz, 1H), 4.02 (s, 3H), 3.95 (s, 3H).
8-(1-Methyl-1H-pyrazol-4-yl)-N-(2-methyl-4-(1-methyl-1H-pyra-
zol-4-yl)phenyl)pyrido[3,4-d]pyrimidin-2-amine 28b.To a solution of
8-chloro-N-(2-methyl-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido-
[3,4-d]pyrimidin-2-amine 27b (12 mg, 0.034 mmol) in 1,4-dioxane/
water (2:1, 3 mL) were added 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-pyrazole (14 mg, 0.068 mmol), cesium carbo-
nate (17 mg, 0.051 mmol), and Pd(PPh3)4 (2 mg, 1.7 μmol). The
reaction mixture was heated to 100 °C under microwave conditions for
30 min. The reaction mixture was diluted with EtOAc and water. The
combined organics were washed with water and brine, dried, and
concentrated in vacuo. The residue was puriﬁed by ﬂash column
chromatography (0−15%MeOH in EtOAc) to give the title compound
(7 mg, 52%). HRMS (ESI) m/z calcd for C22H21N8 (M + H) 397.1884,
found 397.1878. 1H NMR (500 MHz, CDCl3) δ 9.16 (s, 1H), 8.43 (d, J
= 5.5 Hz, 1H), 8.40 (d, J = 5.5 Hz, 2H), 7.86 (d, J = 8.0 Hz, 1H), 7.82 (s,
1H), 7.67 (s, 1H), 7.50−7.45 (m, 2H), 7.36 (d, J = 5.5 Hz, 1H), 7.05 (br
s, 1H), 4.00 (s, 3H), 3.77 (s, 3H), 2.39 (s, 3H).
Preparation of Compounds in Scheme 3 (Exempliﬁed by the
Preparation of 33a). 2-(Methylsulfonyl)-8-(pyrrolidin-1-yl)pyrido-
[3,4-d]pyrimidine 31. A mixture of 8-chloro-2-(methylthio)pyrido[3,4-
d]pyrimidine 16 (105 mg, 0.496 mmol) and pyrrolidine (425 μL, 5.10
mmol) in NMP (2.5 mL) was stirred at 135 °C for 3 h. The mixture was
quenched with aqueous sat. sodium bicarbonate and extracted with
EtOAc. The combined organics were washed with water and brine,
dried, and concentrated in vacuo to aﬀord the crude sulﬁde.
A suspension of crude sulﬁde 29 (ca. 0.496 mmol) in CH2Cl2 (4 mL)
was treated with m-CPBA (77% w/w, 250 mg, 1.11 mmol) at 0 °C and
then allowed to reach rt for 18 h. An additional portion ofm-CPBA (77%
w/w, 60 mg, 0.27 mmol) was added at rt, and the mixture stirred for 2 h.
The mixture was quenched with water and extracted with CH2Cl2. The
combined organics were washed with aqueous sat. sodium bicarbonate
and brine, dried, and concentrated in vacuo. The residue was puriﬁed by
ﬂash column chromatography (0−70% EtOAc in cyclohexane) to give
the title compound (62 mg, 45% over two steps). LCMS (ESI)m/z 279
(M + H). 1H NMR (500 MHz, (CD3)2SO) δ 9.62 (s, 1H), 8.30 (d, J =
5.4 Hz, 1H), 7.11 (d, J = 5.5 Hz, 1H), 3.97 (br s, 4H), 3.45 (s, 3H), 1.98
(s, 4H).
N-(2-Methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-8-(pyrrolidin-
1-yl)pyrido[3,4-d]pyrimidin-2-amine 33a. A solution of 2-methoxy-4-
(1-methyl-1H-pyrazol-4-yl)aniline 23 (52mg, 0.26mmol), TFA (50 μL,
0.65 mmol) and 2-(methylsulfonyl)-8-(pyrrolidin-1-yl)pyrido[3,4-d]-
pyrimidine 31 (35 mg, 0.13 mmol) in 2,2,2-triﬂuoroethanol (0.6 mL)
was heated to 130 °C under microwave irradiation for 2 h. An additional
portion of TFA (50 μL, 0.65 mmol) was added, and the mixture was
heated to 180 °C under microwave irradiation for 2 h. The reaction
mixture was diluted with EtOAc, quenched with aqueous sat. sodium
bicarbonate, and the aqueous layer extracted with EtOAc. The
combined organics were washed with water and brine, dried,
concentrated in vacuo, and puriﬁed by ﬂash column chromatography
(0−100% EtOAc in cyclohexane) to give the title compound (10 mg,
20%). HRMS (ESI)m/z calcd for C22H24N7O (M+H) 402.2037, found
402.2040. 1HNMR (500MHz, (CD3)2SO) δ 9.12 (s, 1H), 8.37 (s, 1H),
8.14 (s, 1H), 7.88 (d, J = 0.9Hz, 1H), 7.87−7.79 (m, 2H), 7.24 (d, J = 1.9
Hz, 1H), 7.17 (dd, J = 8.2, 1.9 Hz, 1H), 6.86 (d, J = 5.4 Hz, 1H), 3.89 (s,
3H), 3.87 (s, 3H), 3.84−3.76 (m, 4H), 1.91−1.81 (m, 4H).
Preparation of Compounds in Scheme 4 (Exempliﬁed by the
Preparation of Compounds 34a, 34f, and 38). N8-Isobutyl-N2-(2-
methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]-
pyrimidine-2,8-diamine 34a. A mixture of 8-chloro-N-(2-methoxy-4-
(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]pyrimidin-2-amine
27a16 (27 mg, 0.074 mmol) and 2-methylpropan-1-amine (100 μL, 1.0
mmol) in NMP (0.7 mL) was stirred at 130 °C in a closed cap vial for 5
h. The reaction mixture was quenched with aqueous sat. sodium
bicarbonate and extracted with EtOAc. The combined organics were
washed with water and brine, dried, and concentrated in vacuo. The
residue was puriﬁed by ﬂash column chromatography (0−80% EtOAc in
cyclohexane) to give the title compound (19 mg, 63%). HRMS (ESI)
m/z calcd for C22H26N7O (M+H) 404.2193, found 404.2177.
1HNMR
(500 MHz, (CD3)2SO) δ 9.16 (s, 1H), 8.43 (s, 1H), 8.19 (d, J = 8.3 Hz,
1H), 8.15 (d, J = 0.8 Hz, 1H), 7.88 (d, J = 0.8 Hz, 1H), 7.77 (d, J = 5.7
Hz, 1H), 7.27 (d, J = 1.9 Hz, 1H), 7.18 (dd, J = 8.2, 1.9 Hz, 1H), 6.88−
6.85 (m, 2H), 3.93 (s, 3H), 3.87 (s, 3H), 3.39−3.28 (m, 2H), 2.00 (hept,
J = 6.8 Hz, 1H), 0.95 (d, J = 6.7 Hz, 6H).
8-(Cyclohexylthio)-N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)-
phenyl)pyrido[3,4-d]pyrimidin-2-amine 34f. Amixture of 8-chloro-N-
(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]-
pyrimidin-2-amine 27a16 (26 mg, 0.071 mmol) and potassium
carbonate (15 mg, 0.11 mmol) in DMF (0.35 mL) was treated with
cyclohexanethiol (12 μL, 0.098 mmol) and stirred at rt for 4 d. An
additional batch of potassium carbonate (10 mg, 0.070 mmol) and
cyclohexanethiol (12 μL, 0.098 mmol) was added, and the mixture
stirred at 50 °C for 18 h. The reaction was quenched with brine and
extracted with EtOAc. The combined organics were washed with water
and brine, dried, and concentrated in vacuo. The residue was puriﬁed by
ﬂash column chromatography (0−80% EtOAc in cyclohexane) to give
the title compound (30 mg, 94%). HRMS (ESI) m/z calcd for
C24H27N6OS (M + H) 447.1962, found 447.1948.
1H NMR (500 MHz,
(CD3)2SO) δ 9.35 (s, 1H), 8.55 (br s, 1H), 8.29 (d, J = 5.4 Hz, 1H), 8.20
(d, J = 0.9 Hz, 1H), 7.93 (d, J = 0.8 Hz, 1H), 7.48 (d, J = 5.4 Hz, 1H),
7.29 (d, J = 1.9 Hz, 1H), 7.26 (dd, J = 8.2, 1.9 Hz, 1H), 3.96 (br s, 4H),
3.87 (s, 3H), 2.17−2.05 (m, 2H), 1.82−1.72 (m, 2H), 1.65 (m, 1H),
1.59−1.40 (m, 4H), 1.35 (m, 1H).
8-(Cyclopropylmethoxy)-2-(methylthio)pyrido[3,4-d]pyrimidine
36. A suspension of 2-(methylthio)pyrido[3,4-d]pyrimidin-8(7H)-one
3516 (502 mg, 2.60 mmol) and silver carbonate (988 mg, 3.58 mmol) in
CHCl3 (25 mL) was treated with bromomethyl cyclopropane (310 μL,
3.19 mmol) and stirred at rt for 18 h. The mixture was heated to 60 °C
for 4 h, and an additional batch of bromomethyl cyclopropane (310 μL,
3.19 mmol) was added. The reaction was heated to 60 °C for 18 h. An
additional batch of bromomethyl cyclopropane (310 μL, 3.19 mmol)
was added and heated for a further 2 h. Et3N was added (6 mL), the
mixture ﬁltered through Celite (CH2Cl2), and concentrated in vacuo.
The residue was puriﬁed by ﬂash column chromatography (0−80%
EtOAc in cyclohexane) to give the title compound (112 mg, 17%).
LCMS (ESI)m/z 248 (M +H). 1H NMR (500MHz, CDCl3) δ 9.14 (s,
1H), 8.07 (d, J = 5.6 Hz, 1H), 7.18 (d, J = 5.6 Hz, 1H), 4.43 (d, J = 7.0
Hz, 2H), 2.74 (s, 3H), 1.48 (m, 1H), 0.73−0.61 (m, 2H), 0.54−0.43 (m,
2H).
8-(Cyclopropylmethoxy)-2-(methylsulfonyl)pyrido[3,4-d]-
pyrimidine 37. A suspension of 8-(cyclopropylmethoxy)-2-
(methylthio)pyrido[3,4-d]pyrimidine 31 (110 mg, 0.445 mmol) in
CH2Cl2 (4 mL) was treated with m-CPBA (77% w/w, 325 mg, 1.35
mmol) at 0 °C and then allowed to reach rt for 18 h. The mixture was
quenched with water and extracted with CH2Cl2. The combined
organics were washed with aqueous sat. sodium bicarbonate, dried, and
concentrated in vacuo. The residue was puriﬁed by ﬂash column
chromatography (0−55% EtOAc in cyclohexane) to give the title
compound (95 mg, 77%). HRMS (ESI) m/z calcd C12H14N3O3S (M +
H) 280.0750, found 280.0748. 1H NMR (500 MHz, (CD3)2SO) δ 9.92
(s, 1H), 8.44 (d, J = 5.7 Hz, 1H), 7.72 (d, J = 5.7 Hz, 1H), 4.43 (d, J = 7.2
Hz, 2H), 3.50 (s, 3H), 1.41(m, 1H), 0.69−0.57 (m, 2H), 0.49−0.40 (m,
2H).
8-(Cyclopropylmethoxy)-N-(2-methoxy-4-(1-methyl-1H-pyrazol-
4-yl)phenyl)pyrido[3,4-d]pyrimidin-2-amine 38. A solution of N-(2-
methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)formamide 26a (30 mg,
0.13 mmol) in THF (1mL) was treated with sodium hydride (60% w/w
dispersion in oil, 8 mg, 0.20 mmol) at 0 °C. After stirring for 40 min at rt,
the mixture was cooled to 0 °C, and 8-(cyclopropylmethoxy)-2-
(methylsulfonyl)pyrido[3,4-d]pyrimidine 37 (46 mg, 0.17 mmol) was
added. The reaction was allowed to reach rt and stirred for 18 h. Sodium
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hydroxide (2 M, 1 mL) and MeOH (1 mL) were added, and the
resulting mixture stirred at rt for 3 h. The mixture was concentrated in
vacuo. The residue was partitioned between EtOAc and water. The
aqueous layer was extracted with EtOAc, and the combined organics
were washed with water and brine, dried, and concentrated in vacuo.
The residue was puriﬁed by ﬂash column chromatography (0−75%
EtOAc in cyclohexane) to give the title compound (27 mg, 52%).
HRMS (ESI) m/z calcd for C22H23N6O2 (M + H) 403.1877, found
403.1871. 1HNMR (500MHz, (CD3)2SO) δ 9.31 (s, 1H), 8.61 (s, 1H),
8.39 (s, 1H), 8.17 (d, J = 0.8Hz, 1H), 7.94−7.84 (m, 2H), 7.35 (d, J = 5.6
Hz, 1H), 7.28 (d, J = 1.8 Hz, 1H), 7.19 (dd, J = 8.3, 1.8 Hz, 1H), 4.33 (d,
J = 6.9 Hz, 2H), 3.94 (s, 3H), 3.88 (s, 3H), 1.40 (m, 1H), 0.68−0.59 (m,
2H), 0.49−0.39 (m, 2H).
Biochemical Assays. MPS1, CDK2, and Aurora A and B
counterscreen assays were performed as reported previously.7
MSD Assay. IC50 of MPS1 autophosphorylation inhibition at
pTpS33/37 sites in HCT116 cells was determined by an electro-
chemiluminescence assay (Meso Scale Discovery, MSD) as described
previously.7
Cell Viability Assay. Cell proliferation assays were carried out by
colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay (Sigma) in HCT116 cells as described previously.7
Crystallization. The kinase domain (residues 519−808) of MPS1
was produced in E. coli and puriﬁed as described previously.10c For
compound 39, apo crystals of MPS1 were grown in PEG300 as
previously described7 prior to soaking in a fresh solution containing 35%
PEG300, 1 mM inhibitor, and 1% (v/v) DMSO for 24 h. The crystal was
cryo-protected in soak solution supplemented with 22.5% ethylene
glycol prior to ﬂash cooling in liquid nitrogen.
Co-crystals of MPS1 with compound S11 were grown at 18 °C using
the sitting-drop vapor-diﬀusion method. The crystallization drops were
composed of 2 μL of protein/ligand solution (8.9 mg/mL protein and 5
mM S11) and 2 μL of reservoir solution placed over 200 μL of reservoir
solution of 18−26% (w/v) PEG3350, 0.1 M bis-Tris propane pH 7.5,
0.1 M MgCl2, and 0.1 M sodium formate in 48-well plates. Co-crystals
typically grew in 12−16 h. Crystals of MPS1 with S11 were transferred
to backsoaking solutions containing reservoir solution also containing
200 mM of inhibitor and up to 20% (v/v) DMSO and incubated at 18
°C for 24−48 h. Crystals were cryo-protected with paratone-N oil prior
to ﬂash cooling in liquid nitrogen.
Co-crystals of MPS1 with compound 34e were grown at 18 °C using
the sitting-drop vapor-diﬀusion method. The crystallization drops were
composed of 2 μL of protein/ligand solution (11.4 mg/mL protein and
2 mM 34e) with 20% (w/v) PEG3350, 0.1 M bis-Tris propane pH 7.5,
and 0.2 M sodium formate. Crystals were cryo-protected with paratone-
N oil prior to ﬂash cooling in liquid nitrogen.
Data Collection, Structure Solution, and Reﬁnement. X-ray
diﬀraction data were collected at 100 K at Diamond Light Source
(Oxfordshire, U.K.) or in-house on a Rigaku FRX with Pilatus 300 K
detector. Data were integrated with XDS24 or MOSFLM (S11 data set
only).25 All data were imported to MTZ format with POINTLESS,26
then scaled and merged with AIMLESS26 in the CCP4 suite.25 The
structures were solved by molecular replacement with PHASER,27 with
the PDB structure 4C4J7 as the search model after removal of all
nonprotein atoms. Structures were reﬁned in iterative cycles of model
building with COOT28 and reﬁnement with BUSTER.29 TLS groups
were selected with PHENIX phenix.ﬁnd_tls_groups.30 Ligand restraints
were generated with GRADE31 and MOGUL.32 The ﬁnal structure
quality was checked with MOLPROBITY.33 The data collection and
reﬁnement statistics are presented in Table S7.
Microsomal Metabolism.Microsomal turnover was carried out in
male CD1 mice, female Sprague−Dawley rats, and pooled human liver
microsomes obtained from Tebu-Bio (Peterborough, U.K.) following
30 min incubation of 10 μM compound in 1 mg/mL microsomal
protein, 3 mmol/L MgCl2, 1 mmol/L NADPH, 2.5 mmol/L, UDP-
glucuronic acid, and 10 mmol/L phosphate buﬀer (pH 7.4) (all
purchased from Sigma-Aldrich, Gillingham, U.K). Reactions, at 37 °C,
were started by addition of the test compound and were terminated at 0
and 30min by the addition of 3 volumes of ice-cold methanol containing
internal standard. Samples were centrifuged at 2800g for 30 min at 4 °C
and the supernatants analyzed. Control incubations were prepared as
above with omission of cofactors. Compound measurements were
performed by LCMS on an Agilent quadrupole time-of-ﬂight instrument
(Agilent 6510) following separation with a 6 min gradient of 10 mM
ammonium acetate in methanol on a 50 × 2.1 mm 2.6μm particles C18
column (Kinetex Phenomenex). For metabolite identiﬁcation, the
gradient was extended to 20 min, andMS/MS carried out with fragment
elucidation for ions of interest.
Pharmacokinetic Studies. All in vivo studies were performed in
accordance with U.K. Home Oﬃce regulations, ICR ethical review
processes, and U.K. National Cancer Research Institute guidelines.34
Female Balb/C mice and Sprague−Dawley rats were obtained from
Charles River (Margate, U.K.). Animals were adapted to laboratory
conditions for at least 1 week prior to dosing and were allowed food and
water ad libitum. Compounds were administered iv or po (mouse: 0.1
mL/10g in 10%DMSO, 5% tween 20 in saline, rat: 0.05 mL/10g in 10%
DMSO, 5% tween 20 in saline). Blood samples were collected from the
tail vein (20 μL) at 8 time points over the 24 h post dose and spotted on
Whatman B cards together with a standard curve and quality controls
spiked in control blood. Cards were allowed to dry at rt for at least 6 h.
Cards were punched, and 6 mm discs were extracted with 200 μL
methanol containing 500 nM olomoucine as an internal standard.
Following centrifugation, extracts were analyzed by multiple reaction
monitoring of precursor and product ions by ESI-LCMS/MS on a
QTRAP 4000 (ABSciex) following separation as above. Quantitation
was carried out with an external calibration (8 points ranging from 1 nM
to 25 μM). Quality controls were included (3 concentrations) at the
beginning and the end of the analytical run and were within 20% of
nominal concentrations.
Pharmacokinetic parameters were derived from noncompartmental
analysis WiniNONlin (model 200 and 201) Pharsight version.
In Vivo Proof-of-Concept Studies. Animals (6−8 week old female
NCr athymic mice) were supplied by a commercial breeder and fed
sterilized food and water ad libitum.
PK/PD Study. Three million HCT116 human colorectal carcinoma
cells were injected s.c. bilaterally into the ﬂanks. Dosing commenced
when tumors reached a mean diameter of 8−10 mm (day 14). Animals
(n = 6 per group) were dosed twice daily with compound 34h (100 mg/
kg po) or vehicle (10% DMSO, 5% Tween 20, 85% saline) over 3 days
(6 doses), and groups of three were culled at 2 or 6 h after the ﬁnal dose.
Heparinized plasma and tumor samples were collected and snap frozen
for pharmacokinetic (PK) and pharmacodynamic (PD) biomarker
analysis.
PD Assays. For PD analysis, frozen tumor samples were
homogenized in RIPA lysis buﬀer (150 mM NaCl, 50 mM Tris pH
7.5, 1 mM EDTA pH 8.0, 1% NP40, 1% sodium deoxycholate, 1%
sodium dodecyl sulfate, and supplemented with protease and
phosphatase inhibitors), sonicated, and centrifuged to clear the debris.
Protein concentrations of the supernatants were measured, and 5 μg
protein for each sample was loaded onto LDS-PAGE (Life
technologies). Proteins were separated, transferred to nitrocellulose
membrane, and probed with phospho-histone H3 (Millipore), total-
histone H3 (Abcam), cleaved-PARP (Cell Signaling), and GAPDH
(Millipore) antibodies. Blots were quantiﬁed using ImageJ and analyzed
with Graphpad Prism.
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